By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ipsen 

39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609


SEARCH JOBS


Industry
Pharmaceutical






Company News
Ipsen (IPN.PA) Announces FDA Approval Of Dysport (Abobotulinumtoxina) For Injection For The Treatment Of Lower Limb Spasticity In Children Aged Two And Older 8/1/2016 11:26:05 AM
Ipsen (IPN.PA) Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Pediatric Patients Aged Two And Older 8/1/2016 9:43:44 AM
Ipsen (IPN.PA)’s First Half 2016 Results 7/28/2016 11:36:25 AM
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Receive Positive CHMP Opinion For Cabometyx (Cabozantinib) For The Treatment Of Advanced RCC In Adults Following Prior VEGF-Targeted Therapy 7/22/2016 9:59:14 AM
Ipsen (IPN.PA) Announces The Acceptance By The European Medicines Agency Of The Marketing Authorization Application For Telotristat Etiprate To Treat Carcinoid Syndrome Caused By Neuroendocrine Tumors, In Combination With Somatostatin Analogues 7/18/2016 10:30:09 AM
As Shire (SHPG) Closes on Baxalta (BXLT), David Meek Takes the Helm at Ipsen (IPN.PA) 7/11/2016 6:16:09 AM
Ipsen (IPN.PA) Release: Endocrine Practice Publishes ELECT Phase III Trial Results In Adults With Carcinoid Syndrome 6/6/2016 8:37:58 AM
ASCO2016: Exelixis (EXEL) And Its Partner Ipsen (IPN.PA) Announce Positive Overall Survival Results From Subgroup Analyses Of Phase III Trial Of CABOMETYX (Cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting 6/6/2016 6:10:47 AM
ASCO2016: Ipsen (IPN.PA) Announces Data Presentations Of Somatuline Depot (Lanreotide) Injection In Gastroenteropancreatic Neuroendocrine Tumors At American Society Of Clinical Oncology Annual Meeting 6/3/2016 7:45:20 AM
Ipsen (IPN.PA)’s Partner Exelixis (EXEL) Announced Results From Randomized Phase 2 Trial CABOSUN That Demonstrate That Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 5/24/2016 10:59:01 AM
12345678910...
//-->